IP Library Granted Patent US 9,005,098
Granted Patent B2
US 9,005,098 · App. 13/925,680 · Granted Apr 14, 2015

Container and method for facilitating disposal of unused pharmaceutical product

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,098
App. No.
13/925,680
Granted
Apr 14, 2015
Kind
B2
Abstract

Containers and methods for disposing unused pharmaceutical product are disclosed. Each container ( 100, 200, 300 ) may include a container body ( 104, 204, 304 ) with an internal chamber ( 116, 216, 316 ) for storing pharmaceutical product, along with a cover ( 124, 224, 324 ) for selectively limiting access to the chamber ( 116, 216, 316 ). An encapsulation component ( 128, 228, 328 ) may be selectively disposable within the chamber ( 116, 216, 316 ), and may be operable to encapsulate the pharmaceutical product within the container ( 100, 200, 300 ). For instance, the encapsulation component ( 128, 228, 328 ) may melt and/or flow into contact with the pharmaceutical product and thereafter solidify to encapsulate the pharmaceutical product. The encapsulation component ( 128, 228, 328 ) may melt and thereafter solidify between the cover ( 124, 224, 324 ) and shell ( 104, 204, 304 ) to limit removal of the cover ( 124, 224, 324 ) from the shell ( 104, 204, 304 ).

Claims (34)

1. A method of managing pharmaceutical product use, comprising the steps of:

opening a pharmaceutical product container comprising a first melting temperature, wherein said pharmaceutical product container comprises a container body and an access member, wherein said opening step comprises moving said access member to an open position to provide access to a chamber within said container body, wherein a plurality of individual pharmaceutical product components are stored within said chamber, wherein each said pharmaceutical product component is an individual dose, and wherein a heat-activated encapsulation component is also disposed within said chamber and has a second melting temperature that is lower than said first melting temperature of said pharmaceutical product container;

removing a first said pharmaceutical product component from said chamber of said pharmaceutical product container after said opening step;

closing said pharmaceutical product container after said removing step, wherein said closing step comprises moving said access member to a closed position to close off said chamber;

heating said pharmaceutical product container after said closing step, wherein said heating step comprises heating said heat-activated encapsulation component to a temperature that is above said second melting temperature of said heat-activated encapsulation component but that is lower than said first melting temperature of said pharmaceutical product container; and

encapsulating said pharmaceutical product components remaining within said chamber of said pharmaceutical product container after said closing step and in response to said heating step.

2. The method of claim 1 , wherein said closing step comprises interlocking said access member with said container body.

3. The method of claim 1 , wherein said closing step comprises detachably securing said access member to said container body.

4. The method of claim 3 , wherein said detachably securing step further comprises threading said access member onto said container body.

5. The method of claim 1 , wherein said encapsulating step comprises at least one of bonding said access member to said container body with encapsulation material from a melting of said heat-activated encapsulation component by said heating step, and contacting said pharmaceutical product components remaining in said pharmaceutical product container with said encapsulation material.

6. The method of claim 1 , wherein said encapsulating step comprises both bonding said access member to said container body with encapsulation material from a melting of said heat-activated encapsulation component by said heating step,and contacting said pharmaceutical product components remaining in said pharmaceutical product container with said encapsulation material.

7. The method of claim 1 , wherein said encapsulating step further comprises allowing encapsulation material, from a melting of said heat-activated encapsulation component by said heating step, to solidify around said pharmaceutical product components remaining within said pharmaceutical product container.

8. The method of claim 1 , wherein said encapsulating step further comprises allowing encapsulation material, from a melting of said heat-activated encapsulation component by said heating step, to solidify between said container body and said access member.

9. The method of claim 1 , wherein said heat-activated encapsulation component is separately incorporated on said access member.

10. The method of claim 1 , further comprising:

allowing said pharmaceutical product container to cool after said heating step.

11. The method of claim 1 , further comprising:

disposing of said pharmaceutical product container, along with said pharmaceutical product components remaining within said pharmaceutical product container, after said heating step.

12. The method of claim 1 , wherein said heating step comprises using a microwave oven.

13. The method of claim 1 , wherein said encapsulating step comprises fixedly sealing said pharmaceutical product container.

14. The method of claim 1 , wherein each said pharmaceutical product Component is selected from the group consisting of a pill, a capsule, a caplet, a tablet, and a patch.

15. A method of managing pharmaceutical product use, comprising the steps of:

opening a pharmaceutical product container comprising pharmaceutical product, wherein each said pharmaceutical product is selected from the group consisting of a pill, a capsule, a caplet, a tablet, and a patch;

removing a first of said pharmaceutical product from said pharmaceutical product container after said opening step;

closing said pharmaceutical product container after said removing step;

heating said pharmaceutical product container after said closing step; and

encapsulating said pharmaceutical product remaining within said pharmaceutical product container after said closing step and in response to said heating step.

16. The method of claim 15 , wherein said pharmaceutical product container comprises a container body and an access member, wherein said opening step comprises moving said access member to an open position, and wherein said closing step comprises moving said access member to a closed position.

17. The method of claim 16 , further comprising the step of:

activating a heat-activated encapsulation material disposed inside said pharmaceutical product container in response to said heating step.

18. The method of claim 17 , wherein said encapsulating step comprises at least one of bonding said access member to said container body with said heat-activated encapsulation material, and contacting said pharmaceutical product remaining in said container with said heat-activated encapsulation material.

19. The method of claim 15 , further comprising:

disposing of said pharmaceutical product container, along with said pharmaceutical product remaining within said pharmaceutical product container, after said heating step.

20. The method of claim 15 , wherein said heating step comprises not heating said pharmaceutical product container above a melting temperature of said pharmaceutical product container.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →